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Summary
 
The expression of the murine interleukin (IL)-2 receptor 
 
a
 
 chain/CD25 is strongly induced at
the transcriptional level after T cell activation. We show here that nuclear factor of activated T
cell (NF-AT) factors are involved in the control of CD25 promoter induction in T cells. NF-
ATp and NF-ATc bind to two sites around positions 
 
2
 
585 and 
 
2
 
650 located upstream of the
proximal CD25 promoter. Immediately 3
 
9
 
 from these NF-AT motifs, nonconsensus sites are
located for the binding of AP-1–like factors. Mutations of sites that suppress NF-AT binding
impair the induction and strong NF-ATp–mediated transactivation of the CD25 promoter in
T cells. In T lymphocytes from NF-ATp–deficient mice, the expression of CD25 is severely
impaired, leading to a delayed IL-2 receptor expression after T cell receptor (TCR)/CD3 stim-
ulation. Our data indicate an important role for NF-AT in the faithful expression of high affin-
ity IL-2 receptors and a close link between the TCR-mediated induction of IL-2 and IL-2 re-
ceptor 
 
a
 
 chain promoters, both of which are regulated by NF-AT factors.
Key words: interleukin 2 receptor • nuclear factor of activated T cells • transcription factors • 
T cells • NF-AT factors
 
T
 
he high affinity IL-2 receptor consists of three individ-
ual polypeptides, the 
 
a
 
, 
 
b
 
, and 
 
g
 
 chains. Although the
 
b
 
 and 
 
g
 
 chains are shared by other lymphokine receptors,
the 
 
a
 
 chain (CD25) is restricted to the IL-2 receptor, and is
expressed by a variety of lymphoid cells (for review see ref-
erence 1). The induction of CD25 in T cells is controlled
at the transcriptional level through two DNA sequence ele-
ments, a proximal promoter/enhancer spanning the nucle-
otides between positions 
 
2
 
54 and 
 
2
 
584 in the mouse and
 
2
 
64 and 
 
2
 
276 in humans, and a distal enhancer spanning
 
z
 
80 nucleotides around position 
 
2
 
1350 in the mouse and
 
2
 
3750 (or 
 
2
 
4150, according to another nomenclature) in
the human CD25 gene (2–6). The activity of the promoter
is rapidly induced by TCR-mediated signals or IL-1, and is
controlled by an array of transcription factors, in particular
by nuclear factor (NF)-
 
k
 
B, Elf-1, SRF, and HMG I(Y).
The induction of the distal enhancer is controlled by IL-2,
which induces signal transducer and activator of transcrip-
tion (Stat)5, a member of the family of Stat transcription
factors. Stat5 binds in concert with Elf-1, HMG I(Y), and
GATA factors to multiple sites of the distal enhancer and
contributes to its IL-2–mediated full expression in activated
peripheral T lymphocytes (4–6).
Nuclear factor of activated T cell (NF-AT) factors com-
prise a family of transcription factors that contribute to the
induced expression of numerous lymphokine and receptor
genes in T cells. Similar to NF-
 
k
 
B factors, the nuclear
translocation and activity of NF-AT factors is stimulated by
TCR-mediated signals (for review see reference 7). The
DNA-binding domains of NF-AT and NF-
 
k
 
B/Rel factors
share a common architecture (8) and, therefore, recognize
overlapping DNA sequence motifs. These common prop-
erties between NF-AT and NF-
 
k
 
B (a major regulator of the
CD25 promoter), and reports on the inhibition of CD25
expression by cyclosporin A (9) (an inhibitor of phos-
phatase calcineurin and, therefore, of nuclear translocation
of NF-AT; reference 7), prompted us to investigate whether
NF-AT factors participate in CD25 promoter control. We
show here that NF-ATp and NF-ATc bind to two sites lo-
cated immediately upstream of the proximal CD25 pro-
moter. Mutations within the NF-AT sites that suppress
NF-AT binding impair CD25 promoter induction. Ac-
cordingly, the induction of CD25 is markedly delayed in T
cells from NF-ATp–deficient mice. These findings impli-
cate an important role for NF-AT factors in the inducible
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expression of high affinity IL-2 receptors after T cell activa-
tion.
 
Materials and Methods
 
Cell Culture, Construction, and Transfection of CD25 Promoter Lu-
ciferase Plasmids.
 
Murine El4 T thymoma cells and human Jurkat
T leukemia cells were grown in RPMI medium containing 5%
FCS. 2 
 
3
 
 10
 
7
 
 cells were transfected using the DEAE dextran pro-
tocol with 2.5 
 
m
 
g DNA of the CD25 promoter-luciferase re-
porter constructs alone or 0.5–2.5 
 
m
 
g DNA of reporter constructs
(as indicated in the figure legends) along with 2 
 
m
 
g of a pLGP3-
based vector expressing full-length murine NF-ATp (NF-AT1-C;
reference 10) or an RSV-LTR vector expressing human NF-
ATc. Human 293 embryonic kidney cells were cultured in
DMEM and transfected using a calcium phosphate transfection
protocol. The luciferase reporter gene construct contains the
wild-type murine CD25 promoter spanning the nucleotides up
to position 
 
2
 
2556 (4). Mutations in one or both of the NF-ATp
binding sites around positions 
 
2
 
585 and 
 
2
 
650 were introduced
into the promoter fragment from 
 
1
 
1 to 
 
2
 
800 using the
QuikChange
 
TM
 
 site-directed mutagenesis kit (Stratagene Corp.,
La Jolla, CA) according to the manufacturer’s instructions.
The following oligonucleotides were used for the mutagenesis
of NF-AT sites:
 
(i) (
 
2
 
667) GCTAGACTTAAAATCTATCATTGCAGCTGTAAACAC (
 
2
 
632)
CGATCTGAATTTTAGATAGTAACGTCGACATTTGTG; and
(ii) (
 
2
 
596) CCCACACCCATGATACTATGAATCGTGCATCAGAG (
 
2
 
562)
GGGTGAGGGTACTATGATACTTAGCACGTAGTCTC
 
The underlined nucleotides indicate the mutations.
 
Immunofluorescence and Flow Cytometry.
 
For Ab stainings, 2–8 
 
3
 
10
 
5
 
 cells were incubated on ice with mAbs at saturating concen-
trations. Fluorescein- and PE-labeled mAbs (Pharmingen, San
Diego, CA) were used for two- and three-color immunofluores-
cence. For three-color flow cytometry, cells were stained first with
biotinylated mAbs (PharMingen) for 15 min and were subse-
quently incubated with streptavidin-Red
 
670
 
 (GIBCO BRL, Eg-
genstein, Germany) and FITC- and PE-labeled mAbs for 15 min.
Results obtained after analysis on a FACScan
 
Ò
 
 flow cytometer
(Becton Dickinson, Mountain View, CA) using Lysys II software
(Becton Dickinson) are shown as log dot-plots or histograms.
 
DNase I Footprint Protection Assays and EMSAs.
 
In DNase I
footprint protection assays, end-labeled DNA probes were pre-
pared using [
 
g
 
-
 
32
 
P]ATP and polynucleotide kinase. 10
 
4
 
 cpm
(
 
z
 
0.2 ng) of the following DNA fragments from the murine
CD25 promoter (4) were used: (
 
a
 
) the HindIII–SacII fragment
spanning the nucleotides from position 
 
1
 
94 to 
 
2
 
268; and (
 
b
 
) the
SacII–BglII fragment spanning the nucleotides from 
 
2
 
268 to
 
2
 
801. Fragment (
 
a
 
) was recut with EspI, and fragment (
 
b
 
) with
DraI generating DNA fragments of 
 
z
 
150–300 bp. These were
incubated for 60 min with a bacterially expressed glutathione
 
S
 
-transferase (GST)–NF-ATp protein (11) containing the DNA-
binding domain of murine NF-ATp. The samples were processed
and fractionated on 6% polyacrylamide, 42% urea-sequencing gels.
Electromobility shift assays (EMSAs) were performed as previ-
ously described (11), using 2 
 
m
 
g nuclear proteins and 0.5 
 
m
 
g poly
[d(I-C)]. In supershift EMSAs, 0.5 
 
m
 
g of either an NF-ATp–spe-
cific Ab (Cat. no. 06-348; UBI) or an NF-ATc–specific mAb
(7A6) (12) were added to the incubations. When the DNA bind-
ing of GST–NF-ATp was tested, 0.5–1.5 
 
m
 
g of bacterial proteins
prepared by affinity column chromatography (11) were incubated
along with 0.5 
 
m
 
g poly [d(I-C)]. The following oligonucleotides
were used as probes:
 
(iii) (
 
2
 
596)gatcCCCACACCCATGGAACTATGAATCGTG (
 
2
 
571)
GGGTGTGGGTACCTTGATACTTAGCACctag;
(iv) (
 
2
 
663)gatcGACTTAAAATCTTCCATTGCAGCTGTA (
 
2
 
635)
CTGAATTTTAGAAGGTAACGTCGACATctag; and
(v) (
 
2
 
667)GCTAGACTTAAAATCTTCCATTGCAGCTGTAAACAC (
 
2
 
632)
CGATCTGAATTTTAGAAGGTAACGTCGACATTTGTG
 
The small letters indicate linker nucleotides.
 
Results and Discussion
 
To determine whether the CD25 promoter is a target
for NF-AT, we cotransfected a CD25 promoter–driven lu-
ciferase reporter gene with NF-ATp– and NF-ATc–spe-
cific expression vectors into El4 T and 293 cells. Treatment
of 293 cells with TPA plus ionomycin (T
 
1
 
I) led to a 
 
,
 
2-
fold, and treatment of El4 cells with T
 
1
 
Con A led to an
8–9-fold, induction of activity of CD25 promoter spanning
the nucleotides up to position 
 
2
 
2556 (4), and to a 12-fold
induction of a shorter CD25 promoter reaching up to
 
2
 
800. Cotransfection of an NF-ATp expression vector
into El4 cells resulted in a strong, 40-fold induction of ac-
tivity of the longer CD25 promoter and in an up to 60-fold
induction of the shorter CD25 promoter fragment after
T
 
1
 
Con A treatment of cells (Fig. 1). Cotransfection with
the NF-ATc vector gave rise to only a slight increase in
promoter activity. In 293 cells, the overexpression of both
NF-AT factors resulted in a six- to ninefold increase in
CD25 promoter activity (Fig. 1).
To demonstrate the binding of NF-ATp to the CD25
promoter, GST–NF-ATp encoding its DNA-binding do-
main was incubated with DNA fragments containing the
first 800 bp of the promoter region in DNase I footprint
Figure 1. NF-ATp transactivates the murine CD25 promoter in T
cells. 2.5 mg DNA of luciferase reporter gene constructs controlled by
murine CD25 promoters up to position 22556 (wt-2556) and 2800 (wt-
800) were transfected into murine El4 T thymoma cells or human embry-
onic 293 kidney cells, along with an empty RSV-based expression vector
or vectors expressing NF-ATp (10) or NF-ATc. The cells were induced
as indicated for 18 h. To calculate the extent of induction, the activity of
the CD25 wild-type promoter in nonstimulated cells was used as a refer-
ence point (onefold). 
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protection assays. Two prominent footprints were de-
tected, spanning the nucleotides from 
 
2
 
577 to 
 
2
 
587 and
 
2
 
639 to 
 
2
 
658, respectively (Fig. 2 
 
A
 
). These comprise the
NF-AT “core” binding sequence TGGAA (7) in opposite
orientations (Fig. 2 
 
B
 
). When probes of these oligonucle-
otides were incubated with GST–NF-ATp in EMSAs,
both probes were bound by NF-ATp, whereas a third
probe spanning the unprotected nucleotides from 
 
2
 
619 to
 
2
 
636 was unable to bind (Fig. 2 
 
C
 
, lanes 
 
13–15
 
). Using
nuclear proteins from murine splenocytes, the generation
of typical inducible NF-AT complexes was detected with
the 
 
2
 
639/
 
2
 
658 probe (Fig. 2 
 
C
 
, lanes 1–6) and, although
far more weakly, with the 2577/2587 probe (Fig. 2 C,
lanes 7–12). The generation of these complexes was enhanced
after induction of cells with T1I (lanes 1, 2, 7, and 8) and
efficiently competed with a 100-fold molar excess of the dis-
tal IL-2 NF-AT site (Fig. 2 C, lanes 6 and 12). Moreover,
the complexes were supershifted in EMSAs using NF-
ATp– and NF-ATc–specific Abs (lanes 3, 4, 9, and 10).
The 2639/2658 site corresponds to a high-affinity NF-
AT binding site. This could be seen best in EMSA compe-
tition assays comparing the binding of NF-AT factors in
nuclear protein preparations from T1I–induced Jurkat cells
to this site and the distal NF-AT site of the murine IL-2
promoter (Fig. 2 D). Although 5–10 ng of the 2639/2658
site was sufficient to suppress almost all NF-AT binding,
10–50 ng of the distal IL-2 NF-AT site was necessary to see
the same effect (Fig. 2 D, lanes 6–11). 50 ng of an AP-1
site was also able to suppress NF-AT complex formation,
whereas the same amount of the upstream promoter site,
i.e., an efficient octamer but poor AP-1 site from the IL-2
promoter (11), was without effect on factor binding (Fig. 2
D, lanes 12–15). In contrast to the 2639/2658 site, the
2577/2587 NF-ATp binding site is a low-affinity NF-AT
site (Fig. 2 C, lanes 7–12; note that lanes 7–12 were ex-
posed five times longer than lanes 1–6).
To demonstrate a functional role for the two NF-ATp
sites, we introduced mutations into the NF-AT motifs of
each site, or into both sites, in the context of the 800-bp
wild-type CD25 promoter fragment. These mutations led
to a loss of NF-AT binding in EMSAs using nuclear pro-
teins from induced Jurkat cells (see Fig. 2 D, lanes 18–20)
Figure 2. Binding of NF-AT
to the CD25 promoter. (A)
DNase I footprint protection as-
say. A CD25 promoter probe
spanning the nucleotides from
2548 to 2804 was incubated
with 3 and 5 mg BSA (lanes 3
and 4) or 1–5 mg GST–NF-ATp
protein (lanes 5–9). The NF-
ATp–specific footprints are indi-
cated.  G and G1A, chemical
sequencing reactions. (B) Se-
quences of footprint regions.
The footprints are indicated in
brackets. The arrows indicate the
direction of TGGAA NF-AT
“core” motifs. The TPA respon-
sive element–like sequence mo-
tifs 39 from the NF-AT motifs
are boxed. (C) EMSAs with the
NF-AT sites. In lanes 1–12, nu-
clear proteins from murine sple-
nocytes are shown, and in lanes
13–15, GST–NF-ATp was used
with the 2639/2658 (lanes 1–6
and 13) and 2577/2587 probes
(lanes 7–12 and 15). In lane 14, a
probe of the 2610/2636 site
was used as a control. 2 mg of
nuclear proteins from unin-
duced splenocytes (2) or spleno-
cytes induced for 2 h with T1I
(1) were incubated in the ab-
sence or presence of 0.5 mg NF-
ATc– or NF-ATp–specific Abs,
or in the presence of a 200-fold
molar excess of homologous un-
labeled probes or distal IL-2 NF-
AT site as indicated. Note that the autoradiograph of lanes 1–6 was exposed for 16 h, and that of lanes 7–12 for 3 d. NS, nonspecific complex. Free
probes are cut off. (D) EMSAs of the 2639/2658 site using nuclear proteins from Jurkat cells. A probe of the 2639/2658 site was incubated with 2 mg
of nuclear proteins from Jurkat cells treated with T1I in the absence or presence of 100 ng/ml cyclosporin A (CsA). For competition the following
DNAs were used: 5–50 ng of the cold 2639/2658 site and the distal IL-2 NF-AT site, or 10 and 50 ng of the proximal IL-2 octamer site (11) and a con-
sensus AP-1 site. In lanes 16 and 17, 0.5 mg of NF-AT–specific Abs were added. In lanes 18–20, a 2632/2667 probe mutated in the NF-AT site (see
oligonucleotide a in Materials and Methods) was incubated without or with NF-AT–specific Abs.1372 NF-AT Controls the CD25 Promoter
or GST–NF-ATp (data not shown). When the mutated
CD25 promoter/luciferase constructs were transfected into
El4 T cells alone or with an NF-ATp expression vector
their induction was severely impaired compared with the
wild-type promoter. The T1Con A–mediated 16-fold in-
duction of the 800-bp CD25 promoter fragment was al-
most abolished (Fig. 3 A) and its .25-fold transactivation
by NF-ATp was reduced to a 2–3-fold increase for the
mutated promoter (Fig. 3 B).
The importance of NF-ATp sites for the CD25 expres-
sion is underlined by defects in the CD25 surface expres-
sion on LN T cells from NF-ATp2/2 mice established in
our laboratory (13). When LN T cells from wild-type mice
were stimulated with plate-bound a-CD3 Abs for 2–24 h
in vitro, a marked increase of CD25 surface expression was
detected after 6–12 h, which became even more pro-
nounced after 24 h. Due to the strong stimulation of the
CD25 promoter by secreted IL-2 (2), .50% of T cells ex-
press large amounts of CD25 48 h after stimulation (Fig. 4).
On NF-ATp2/2 LN T cells, CD25 expression was found to
be distinctly delayed, becoming clearly detectable only 24 h
after induction in spite of high, unimpaired IL-2 production
of NF-ATp2/2 T cells (13). In addition, fewer cells ex-
pressed high levels of CD25 after induction for 48 h (Fig. 4).
The two NF-ATp binding sites are located near the
CD25 promoter and therefore appear to be involved in the
rapid induction of the murine CD25 gene in resting T
cells. The core sequences of these sites, TGGAA, differ
slightly from the AGGAAAA core motifs of the IL-2 and
IL-4 promoters and are the strongest NF-ATp binding sites
in the human GM-CSF enhancer (14). As indicated in Fig.
2 B, 7–9 bp 39 to the NF-AT motifs are situated TPA-
responsive element–like sequences that might allow the con-
certed binding of AP-1 and NF-AT. In EMSAs we detected
a specific binding of GST–c-Jun to both sites (data not
shown), but it remains to be shown which proteins of the
AP-1 family bind and regulate the CD25 promoter in vivo.
Finally, it should be pointed out that several properties of
NF-ATp2/2 mice, such as the impaired clonal deletion of
T cells and expansion of lymphoid organs (13, 15, 16), are
shared by the mice deficient for IL-2 and IL-2 receptors
(17–19). We assume that the impaired CD25 expression
might contribute to the development of this phenotype in
NF-ATp2/2 mice, which is reminiscent of other mice with
defects in the IL-2 signaling system.
Figure 3. The NF-ATp sites contribute to the induction of CD25 promoter. (A) Mutations within the NF-ATp sites that suppress NF-AT binding in-
terfere with the T1Con A–mediated CD25 promoter induction in El4 cells. 2.5 mg of luciferase constructs containing the wild-type CD25 promoter up
to 2800 bp or a promoter with mutations in the 2658/2639 (mut. 1), the 2587/2577 site (mut. 2), or in both sites (mut. 112) was transfected into El4
cells that were induced for 12 h. (B) Mutations of NF-AT sites suppress the NF-ATp–mediated transactivation of the CD25 promoter. 0.5 mg of the
CD25 luciferase constructs was cotransfected with an NF-ATp expression vector into El4 cells that were stimulated for 12 h. To calculate the extent of
induction, the activity of the CD25 wild-type promoter in nonstimulated cells was used as a reference point (onefold).
Figure 4. Impaired CD25 expres-
sion on NF-ATp2/2 LN T cells. LN
T cells from NF-ATp1/1 and NF-
ATp2/2 mice (13) were treated with
plate-bound a-CD3 mAb in vitro.
The cells were stained with mAbs
directed against murine CD25 (7D4;
PharMingen) and a/b-TCR (H57-
597; PharMingen). The expression
of CD25 on a/b-TCR1 LN cells is
shown. The lowest panel shows a
comparison of CD25 expression on
NF-ATp1/1 and NF-ATp2/2
TCR1 LN cells stimulated for 24 h.
The dotted line indicates the isotype
control staining of LN cells.1373 Schuh et al. Brief Definitive Report
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